Joris Vandenbossche

JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection

Fabien Zoulim, Oliver Lenz, Joris Vandenbossche et al. · Gastroenterology · 2020 · 116 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection

Harry L.A. Janssen, Jinlin Hou, Tarik Asselah et al. · Gut · 2023 · 55 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data

Harry L.A. Janssen, Jinlin Hou, Tarik Asselah et al. · Journal of Hepatology · 2020 · 37 citations

Medicine, Internal Medicine, Hepatology +8

Randomized 5‐Treatment Crossover Study to Assess the Effects of External Heat on Serum Fentanyl Concentrations During Treatment With Transdermal Fentanyl Systems

Kenneth Todd Moore, Gayatri Sathyan, Ute Richarz et al. · The Journal of Clinical Pharmacology · 2011 · 28 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects

Joris Vandenbossche, Wolfgang Jessner, Maarten van den Boer et al. · Advances in Therapy · 2019 · 28 citations

Pharmacy, Pharmacokinetics, Pharmacology +11